This review summarizes promising new targets and immunotherapy combination strategies currently under clinical development.
Scott J. Antonia, MD, PhD
Advertisement
Articles by Scott J. Antonia, MD, PhD
If we are to provide new options for the large numbers of NSCLC patients with no actionable mutation, we must focus on identifying new mutations through tissue acquisition. In the meantime, these patients are ideal candidates for the large number of available immunotherapy trials.
Advertisement
Latest Updated Articles
- Adapting to the Brave New World of Lung Cancer Treatment
Published: May 15th 2013 | Updated:
- Propelling Immunotherapy Combinations Into the Clinic
Published: December 16th 2015 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
3
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
4
Case 2: Patient With High-Risk RRMM Relapsing After BCMA CAR T-Cell Therapy
5
